Anupam Rasayan India Ltd. has announced a significant acquisition, entering into a definitive agreement to acquire a 43.3-48.2% equity stake in Bliss GVS Pharma Limited. The acquisition also includes an open offer to the public shareholders of Bliss GVS Pharma, a company known for its pharmaceutical formulations.
The acquisition is part of Anupam Rasayan’s strategic plan to expand its presence in the pharmaceutical sector. The total purchase consideration for this acquisition is financed through a term loan of ₹300 crores and a non-controlling non-voting equity instrument for the remaining amount.
Bliss GVS Pharma Limited, established in 1984, is a prominent player in the pharmaceutical industry, focusing on the development, manufacturing, marketing, and export of various dosage forms, including suppositories, pessaries, tablets, capsules, syrups, injectables, creams, and ointments. The company has a strong international presence, particularly in Africa, Asia, and Latin America, and is recognised for its leadership in suppositories and pessaries.
Anupam Rasayan’s Managing Director, Anand Desai, commented on the acquisition, stating that it marks an important milestone in the company’s vision of building an integrated global life sciences and specialty pharmaceutical platform. He highlighted that the acquisition would strategically strengthen Anupam Rasayan’s presence across the pharmaceutical value chain, enhance global reach, and unlock significant synergies through expanded product offerings and improved customer engagement.
Anupam Rasayan India Ltd., incorporated in 1984, is a leading company in the custom synthesis and manufacturing of specialty chemicals in India. The company operates multiple manufacturing facilities and serves a diverse base of Indian and global customers.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).